rBCG-LTAK63
Candidate Overview
rBCG-LTAK63 is an unmarked recombinant BCG strain expressing the subunit A of detoxified E. coli Heat-Labile Toxin (LTAK63) as adjuvant. rBCG-LTAK63 induced protection superior to standard BCG, through enhanced and regulated Th1/Th17 responses, and both early effector and long-term TRM cell responses with reduced lung inflammation and improved immunopathological control.
Sponsor / Lead Developer: Instituto Butantan
Primary Indication: Prevention of TB disease
Other Indication(s): Immunotherapy/Shortening TB treatment and Prevention of TB recurrence
Target Population(s): Adults and Infants
Target Route of Administration: Intradermal
Immune tissue localization: Lung and Lymph node
Immunological responses: T-cell
Preclinical Animal Models: Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 CD8 Natural Killer (NK) |
|
| T-cell functional profile | IFN-γ TNF-α IL-17 |
|
| Preferential immune tissue localization | Lung Lymph node |
|
| Trained immunity | Yes | |
Related Publications
- rBCG-LTAK63 enhances protection against tuberculosis by inducing autophagy and circadian gene regulation. (Front. Immunol., 2025)
- Recombinant BCG expressing the LTAK63 adjuvant increased memory T cells and induced long-lasting protection against Mycobacterium tuberculosis challenge in mice. (Front. Immunol., 2023)
- Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages (Vaccines, 2022)
- CRISPR/Cas9 Approach to Generate an Auxotrophic BCG Strain for Unmarked Expression of LTAK63 Adjuvant: A Tuberculosis Vaccine Candidate. (Front. Immunol., 2022)
- Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria (Hum Vaccin Immunother., 2019)
- Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis (Sci Rep., 2017)